BioMarin Pharmaceutical logo

BioMarin PharmaceuticalNASDAQ: BMRN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 July 1999

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$12.09 B
-44%vs. 3y high
94%vs. sector
-96%vs. 3y high
67%vs. sector
-53%vs. 3y high
60%vs. sector
-58%vs. 3y high
58%vs. sector

Price

pre-market | 63 min ago
$63.45+$0.04(+0.06%)

Dividend

No data over the past 3 years
$745.74 M$712.35 M
$745.74 M$106.08 M

Analysts recommendations

Institutional Ownership

BMRN Latest News

Can BioMarin Stock Live Up to Wall Street's High Expectations?
marketbeat.com22 November 2024 Sentiment: NEGATIVE

BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%.

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
seekingalpha.com21 November 2024 Sentiment: POSITIVE

Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth.

BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
prnewswire.com16 November 2024 Sentiment: POSITIVE

SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia.

BioMarin to Participate in Three Upcoming Investor Conferences
prnewswire.com06 November 2024 Sentiment: POSITIVE

UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
zacks.com05 November 2024 Sentiment: POSITIVE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com04 November 2024 Sentiment: POSITIVE

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BioMarin (BMRN) Upgraded to Buy: Here's Why
zacks.com04 November 2024 Sentiment: POSITIVE

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
zacks.com04 November 2024 Sentiment: POSITIVE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BMRN vs. INCY: Which Stock Is the Better Value Option?
zacks.com04 November 2024 Sentiment: NEUTRAL

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks?

BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
zacks.com30 October 2024 Sentiment: POSITIVE

BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.

What type of business is BioMarin Pharmaceutical?

BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative treatments for people with serious and life-threatening rare diseases and medical conditions. BioMarin was founded in 1996 and is headquartered in San Rafael, California. The company's portfolio includes several commercial products and several clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Aldurazyme - a drug for the treatment of the genetic disease mucopolysaccharidosis; Brineura - a drug for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, also known as Batten disease; and Kuvan (tetrahydrobiopterin) - a patented synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disorder; among others.

What sector is BioMarin Pharmaceutical in?

BioMarin Pharmaceutical is in the Healthcare sector

What industry is BioMarin Pharmaceutical in?

BioMarin Pharmaceutical is in the Biotechnology industry

What country is BioMarin Pharmaceutical from?

BioMarin Pharmaceutical is headquartered in United States

When did BioMarin Pharmaceutical go public?

BioMarin Pharmaceutical initial public offering (IPO) was on 26 July 1999

What is BioMarin Pharmaceutical website?

https://www.biomarin.com

Is BioMarin Pharmaceutical in the S&P 500?

No, BioMarin Pharmaceutical is not included in the S&P 500 index

Is BioMarin Pharmaceutical in the NASDAQ 100?

No, BioMarin Pharmaceutical is not included in the NASDAQ 100 index

Is BioMarin Pharmaceutical in the Dow Jones?

No, BioMarin Pharmaceutical is not included in the Dow Jones index

When was BioMarin Pharmaceutical the previous earnings report?

No data

When does BioMarin Pharmaceutical earnings report?

The next expected earnings date for BioMarin Pharmaceutical is 21 February 2025